# BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma

> **NCT03836768** · PHASE1 · COMPLETED · sponsor: **Zhejiang DTRM Biopharma** · enrollment: 20 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** DTRMWXHS-12

## Key facts

- **NCT ID:** NCT03836768
- **Lead sponsor:** Zhejiang DTRM Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-11
- **Primary completion:** 2021-11-17
- **Final completion:** 2021-11-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836768, "BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03836768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*